Literature DB >> 33729455

Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival.

Emmanuel Bachy1,2, James R Cerhan3, Gilles Salles1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33729455      PMCID： PMC7993099          DOI： 10.1182/bloodadvances.2020003797

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  7 in total

1.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

2.  Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Authors:  John F Seymour; Robert Marcus; Andrew Davies; Eve Gallop-Evans; Andrew Grigg; Andrew Haynes; Michael Herold; Thomas Illmer; Herman Nilsson-Ehle; Martin Sökler; Ulrich Dünzinger; Tina Nielsen; Aino Launonen; Wolfgang Hiddemann
Journal:  Haematologica       Date:  2020-05       Impact factor: 9.941

3.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

4.  A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

Authors:  Emmanuel Bachy; Matthew J Maurer; Thomas M Habermann; Bénédicte Gelas-Dore; Delphine Maucort-Boulch; Jane A Estell; Eric Van den Neste; Réda Bouabdallah; Emmanuel Gyan; Andrew L Feldman; Joan Bargay; Alain Delmer; Susan L Slager; Maria Gomes da Silva; Olivier Fitoussi; David Belada; Hervé Maisonneuve; Tanin Intragumtornchai; Stephen M Ansell; Thierry Lamy; Peggy Dartigues; Brian K Link; John F Seymour; James R Cerhan; Gilles Salles
Journal:  Blood       Date:  2018-04-17       Impact factor: 22.113

5.  Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

Authors:  Qian Shi; Norbert Schmitz; Fang-Shu Ou; Jesse G Dixon; David Cunningham; Michael Pfreundschuh; John F Seymour; Ulrich Jaeger; Thomas M Habermann; Corinne Haioun; Hervé Tilly; Hervé Ghesquieres; Francesco Merli; Marita Ziepert; Raoul Herbrecht; Jocelyne Flament; Tommy Fu; Bertrand Coiffier; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2018-07-05       Impact factor: 44.544

6.  Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

Authors:  Qian Shi; Christopher R Flowers; Wolfgang Hiddemann; Robert Marcus; Michael Herold; Anton Hagenbeek; Eva Kimby; Howard Hochster; Umberto Vitolo; Bruce A Peterson; Emmanuel Gyan; Michele Ghielmini; Tina Nielsen; Sabine De Bedout; Tommy Fu; Nancy Valente; Nathan H Fowler; Eva Hoster; Marco Ladetto; Franck Morschhauser; Emanuele Zucca; Gilles Salles; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

7.  Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

Authors:  Emmanuel Bachy; John F Seymour; Pierre Feugier; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; John V Catalano; Pauline Brice; François Lemonnier; Alejandro Martin; Olivier Casasnovas; Lars M Pedersen; Véronique Dorvaux; David Simpson; Sirpa Leppa; Jean Gabarre; Maria G da Silva; Sylvie Glaisner; Loic Ysebaert; Anne Vekhoff; Tanin Intragumtornchai; Steven Le Gouill; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Jonathan Farhi; Harald Zeuner; Hervé Tilly; Gilles Salles
Journal:  J Clin Oncol       Date:  2019-07-24       Impact factor: 44.544
  7 in total
  2 in total

Review 1.  Time for an individualized approach to first-line management of follicular lymphoma.

Authors:  Guillaume Cartron; Judith Trotman
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

Review 2.  Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation.

Authors:  Emmanuel Bachy; Kaspar Rufibach; Joana Parreira; Aino Launonen; Tina Nielsen; Allan Hackshaw
Journal:  Adv Ther       Date:  2021-05-26       Impact factor: 3.845
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.